These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 33383825)
1. Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign. Gomez-Gutierrez P; Perez JJ Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383825 [TBL] [Abstract][Full Text] [Related]
2. Are noscapine and raloxifene ligands of the bradykinin B Bachelard H; Marceau F Int Immunopharmacol; 2022 Sep; 110():108984. PubMed ID: 35780642 [TBL] [Abstract][Full Text] [Related]
3. FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys. Sharif NA; Katoli P; Scott D; Li L; Kelly C; Xu S; Husain S; Toris C; Crosson C Drug Dev Res; 2014 Jun; 75(4):211-23. PubMed ID: 24796320 [TBL] [Abstract][Full Text] [Related]
4. MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization. Cucchi P; Meini S; Bressan A; Catalani C; Bellucci F; Santicioli P; Lecci A; Faiella A; Rotondaro L; Giuliani S; Giolitti A; Quartara L; Maggi CA Eur J Pharmacol; 2005 Dec; 528(1-3):7-16. PubMed ID: 16324696 [TBL] [Abstract][Full Text] [Related]
5. Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. Iaconis D; Bordi L; Matusali G; Talarico C; Manelfi C; Cesta MC; Zippoli M; Caccuri F; Bugatti A; Zani A; Filippini F; Scorzolini L; Gobbi M; Beeg M; Piotti A; Montopoli M; Cocetta V; Bressan S; Bucci EM; Caruso A; Nicastri E; Allegretti M; Beccari AR Cell Death Dis; 2022 May; 13(5):498. PubMed ID: 35614039 [TBL] [Abstract][Full Text] [Related]
6. Raloxifene as a treatment option for viral infections. Hong S; Chang J; Jeong K; Lee W J Microbiol; 2021 Feb; 59(2):124-131. PubMed ID: 33527314 [TBL] [Abstract][Full Text] [Related]
7. Preliminary mutational analysis of the human kinin B2 receptor for nonpeptide antagonist ligands recognition. Meini S; Cucchi P; Zappitelli S; Rotondaro L; Quartara L; Giolitti A; Maggi CA Can J Physiol Pharmacol; 2002 Apr; 80(4):303-9. PubMed ID: 12025965 [TBL] [Abstract][Full Text] [Related]
8. A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor: evidence from mutational analysis. Bellucci F; Meini S; Cucchi P; Catalani C; Reichert W; Zappitelli S; Rotondaro L; Quartara L; Giolitti A; Maggi CA Br J Pharmacol; 2003 Oct; 140(3):500-6. PubMed ID: 12970081 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of canine bradykinin receptors in prostatic culture and in isolated prostate. Srinivasan D; Burbach LR; Daniels DV; Ford AP; Bhattacharya A Br J Pharmacol; 2004 May; 142(2):297-304. PubMed ID: 15155537 [TBL] [Abstract][Full Text] [Related]
10. The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B2 receptor. Bellucci F; Meini S; Cucchi P; Catalani C; Giuliani S; Zappitelli S; Rotondaro L; Quartara L; Giolitti A; Maggi CA Eur J Pharmacol; 2004 May; 491(2-3):121-5. PubMed ID: 15140628 [TBL] [Abstract][Full Text] [Related]
11. Functional studies of bradykinin receptors in Chinese hamster ovary cells stably expressing the human B2 bradykinin receptor. Zhang SP; Wang HY; Lovenberg TW; Codd EE Int Immunopharmacol; 2001 May; 1(5):955-65. PubMed ID: 11379050 [TBL] [Abstract][Full Text] [Related]
16. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. Bawolak MT; Gera L; Morissette G; Stewart JM; Marceau F J Pharmacol Exp Ther; 2007 Nov; 323(2):534-46. PubMed ID: 17699739 [TBL] [Abstract][Full Text] [Related]
17. A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile. Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Aramori I; Hatori C; Oku T; Tanaka H J Med Chem; 2004 May; 47(10):2667-77. PubMed ID: 15115408 [TBL] [Abstract][Full Text] [Related]
18. Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery. Chen H; Wu J; Gao Y; Chen H; Zhou J Curr Top Med Chem; 2016; 16(19):2107-14. PubMed ID: 26881709 [TBL] [Abstract][Full Text] [Related]
19. Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. Duarte RRR; Copertino DC; Iñiguez LP; Marston JL; Bram Y; Han Y; Schwartz RE; Chen S; Nixon DF; Powell TR Mol Med; 2021 Sep; 27(1):105. PubMed ID: 34503440 [TBL] [Abstract][Full Text] [Related]
20. Identification of raloxifene as a novel α-glucosidase inhibitor using a systematic drug repurposing approach in combination with cross molecular docking-based virtual screening and experimental verification. Wu J; Hu B; Lu S; Duan R; Deng H; Li L; He L; Zhao Y; Wang J; Yu Z Carbohydr Res; 2022 Jan; 511():108478. PubMed ID: 34801925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]